EudraCT Nr. 2013-004502-26, Diabetes, Novo Nordisk, Phase III (2014-2015)
Efficacy and safety of semaglutide once-weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with typ 2 diabetes.
EudraCT Nr. 2013-003075-35, COPD, GlaxoSmithKline UK, Phase III (2014-2015)
A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease.
EudraCT Nr. 2013-004392-12, Diabetes, Novo Nordisk, Phase III (2014-2015)
Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes.
EudraCT Nr. 2013-004297-98, COPD, GlaxoSmithKline UK, Phase III (2014-2015)
Study MEA117113: Mepalizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level.
EudraCT Nr. 2013-001473-24, Diabetes, Eli Lilly, Phase IV (2014-2015)
An individualized treatment approach for older patients: A randomized, controlled study in type 2 diabetes mellitus.
EudraCT Nr. 2013-002239-44, COPD, GlaxoSmithKline UK, Phase III (2013-2014)
A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VL in subjects with Chronic Obstructive Pulmonary Disease (COPD).
EudraCT Nr. 2006-003622-29, Cardiovascular Disease, Bayer, Phase III (2008-2017)
The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study to Assess the Efficacy (Reduction of Cardivascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicyl Acid in Patients at Moderate Risk of Cardiovascular Disease.
EudraCT Nr. 2008-004104-31, Chronic heart failure, Novartis, Phase III (2009-2015)
A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II-IV).
PraCMan, University of Heidelberg, (2011-2013)
Primary care practice-based care management for chronically ill patients.
EudraCT-Nr. 2012-001870-27, COPD, GlaxoSmithKline UK, Phase III (2013)
A randomized, double-blind, parallel group study to evaluate the efficacy and safety of fluticasone propionate/salmeterol 250/50mcg twice-daily plus GSK573719 Inhalation Powder 62.5mcg once-daily or GSK573719 Inhalation Powder 125mcg once-daily in subjects with COPD.
EudraCT Nr. 2008-002199-88, Diabetes, Novo Nordisk, Phase III (2011-2013)
Effect of liraglutide on body weight in overweight or obese sujects with type 2 diabetes. A 56 week randomised, double-blind, placebo-controlled, three armed parallel group, multi-centre, multinational trial with a 12 week observational follow up period.
EudraCT Nr. 2010-021560-15, Diabetes, Novo Nordisk, Phase III (2011-2012)
A 26 week randomised, parallel three-arm, open-label, multi-centre, multinational treat-to-target trial comparing fixed ratio combination of insulin degludec and liraglutide versus insulin degludec or liraglutide alone in subjects with type 2 diabetes treated with 1-2 oral anti-diabetic drugs.
EudraCT Nr. 2010-021800-72, COPD, GlaxoSmithKline UK, Phase III (2011-2012)
A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GW642444 and with tiotropium over 24 weeks in sujects with COPD.
EudraCT Nr. 2011-000518-21, Diabetes, Novartis, Phase IV (2011-2012)
Cross-over study to assess the difference in fasting plasma glucose (FPG) between vildagliptin (Galvus®/Eucreas®) and sitagliptin (Januvia®/Janumet®) after two weeks (FPG-VISIT).
EudraCT Nr. 2009-010913-59, Diabetes, Sanofi-Aventis, Phase IV (2011-2012)
Health Assessment, Patient treatment satisfaction and Quality-of-Life in insulin-naive type 2 diabetes Patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin gl...
EudraCT Nr. 2008-007831-41, Hypertension, Novartis, Phase IV (2009-2010)
A twelve-week, randomized, double-blind, parallel group study to evaluate th prolonged efficacy and safety of aliskiren 300 g compared to telmisartan 80 mg in mild to moderate hypertensive patients.
getABI, epidemiological trial, (2002-2008)
German epidemiological trial on ankle brachial index for elderly patients in family practice to dedect peripheral arterial disease, significant marker for high mortality.